急性肾损伤对抗癌治疗剂量和长期结局的影响:EORTC试验汇总分析
该研究汇总9项EORTC试验、2872例晚期癌症患者,采用血清肌酐和研究者报告的不良事件识别AKI。基线eGFR对PFS和OS均无影响;AKI降低治疗剂量强度但不增加停药率,首次RIFLE事件显著降低PFS(汇总HR=1.18,95%CI 1.07-1.30;P=0.0012),对OS影响异质性较大。
要点
- 基线eGFR对晚期癌症患者PFS和OS无影响。
- AKI降低治疗剂量强度但不增加治疗停药率。
- 首次RIFLE事件显著降低PFS(汇总HR=1.18)。
核心结论
- AKI与抗癌治疗剂量强度降低和PFS缩短相关。
- 建议治疗早期密切监测肾功能以早期诊断和管理AKI。
- 需要肿瘤科与肾内科协作以减少AKI患者治疗不足的风险。
研究设计与样本
- 回顾性汇总分析,纳入欧洲癌症研究与治疗组织(EORTC)开展的9项试验。
- 共2872例晚期转移性癌症患者,涵盖多种肿瘤类型和多种全身治疗类型。
- AKI通过血清肌酐水平和研究者报告的不良事件识别。
- 采用荟萃分析方法获得AKI对剂量强度、治疗持续时间、PFS和OS影响的汇总估计。
主要发现
- 基线eGFR对PFS或OS均无影响,且各试验间同质。
- 多数RIFLE事件发生在治疗过程早期。
- AKI不增加治疗停药率,但降低研究治疗剂量强度。
- 首次RIFLE事件显著且同质地降低PFS(汇总HR=1.18,95%CI 1.07-1.30;P=0.0012)。
- AKI对OS的影响在各试验间异质性较大。
临床怎么用
- 治疗最初几个月应密切监测肾功能,以便早期发现和管理AKI。
- 临床试验方案和日常实践中应考虑将肾功能监测纳入。
- 肿瘤科与肾内科应协作,减少AKI患者治疗不足的风险。
局限性
- 为回顾性分析。
- AKI识别依赖血清肌酐和研究者报告的不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The impact of kidney dysfunction on long-term outcomes of patients with advanced cancer remains unclear. METHODS: Patients with advanced cancer included in trials conducted by the European Organisation for Research and Treatment of Cancer were eligible for this retrospective analysis. Acute kidney injury (AKI) was identified using serum creatinine levels and using adverse events reported by investigators. The impact of baseline estimated glomerular filtration rates (eGFRs) on progression-free survival (PFS) and overall survival (OS) was investigated. Pooled estimates of the impact of AKI on dose intensity, treatment duration, PFS and OS were obtained following a meta-analytic process. RESULTS: Nine trials were included in this study, totalling 2872 metastatic patients with various tumour types and various systemic treatment types. Baseline eGFR had homogeneously no impact on PFS or OS. Most Risk, Injury, Failure, Loss of kidney function and End-stage kidney disease (RIFLE) events occurred early during the course of the treatment. AKI was not associated with an increased rate of treatment discontinuation, while it decreased the study treatment dose intensity. Occurrence of a first RIFLE event significantly and homogeneously reduced PFS (pooled hazard ratio = 1.18, 95% confidence interval 1.07-1.30; P = 0.0012), while its impact on OS was more heterogeneous across trials. CONCLUSION: AKI is associated with reduced treatment dose intensity and reduced PFS. Therefore, close monitoring of the kidney function during the first months of treatment should be included in clinical trial protocols and probably also in daily practice to enable early AKI diagnosis and management. Collaboration between oncologists and nephrologists is needed to reduce the risk of undertreatment of patients experiencing AKI.
引用
- Péron J, Neven A, Collette L, et al. Impact of acute kidney injury on anticancer treatment dosage and long-term outcomes: a pooled analysis of European Organisation for Research and Treatment of Cancer trials. Nephrol Dial Transplant. 2020. PMID: 32337562. doi:10.1093/ndt/gfaa049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。